Drugs / Infanrix
Infanrix
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 36 trials · 1 met primary | ||||||
| Phase 3 | NCT02096263 | Apr 2014 → Feb 2015 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, poliomyelitis +1 | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01000974 | Jun 2010 → Nov 2011 | haemophilus infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00696423 | Jun → Jul 2008 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00614614 | Feb 2008 → Jul 2009 | meningococcal infection | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT00412854 | Jan → Jun 2007 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00197236 | Nov 2003 → Dec 2007 | hepatitis A virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 43 trials · 1 met primary | ||||||
| Phase 4 | NCT01094171 | Dec 2010 → Oct 2012 | poliomyelitis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00289913 | Apr 2006 → Jun 2010 | hepatitis A virus infection | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 4 | NCT00544271 | May 2003 → Jan 2004 | diphtheria, tetanus | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00482781 | Sep 2000 → Sep 2004 | infantile apnea | American SIDS Institute | Completed | No outcome recorded |
| Comparator or background therapy9 trials | ||||||
| Phase 2 | NCT00729001 Background | Nov 2000 → Sep 2002 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT07160244 Background | Aug 2025 → Nov 2028 expected | — | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT02640703 Comparator | Mar 2015 → Dec 2016 | — | University Hospital Tuebingen | Completed | No outcome recorded |
| Phase 3 | NCT01627561 Comparator | Oct 2012 → Apr 2014 | human papilloma virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01171963 Background | Aug 2010 → May 2012 | Rotavirus infection | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT00990080 Comparator | May → Jul 2010 | — | Dalhousie University | Completed | No outcome recorded |
| Phase 3 | NCT01003431 Comparator | Dec 2009 → Aug 2010 | Rotavirus infection, diphtheria, pertussis, tetanus | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded |
| Phase 3 | NCT00148941 Comparator | Jan 2005 → Nov 2006 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT02002156 Background | Jun 2014 → Aug 2016 | tuberculosis | University of Oxford | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Infanrix | “Subjects received Infanrix co-administered with ActHIB at Day 0, followed by one dose of Havix at Day 30” NCT00197236 ↗ |
| Known as | Infanrix---IPV---Hib, GlaxoSmithKline | “Infanrix™---IPV---Hib, GlaxoSmithKline” NCT02002156 ↗ |
| Known as | Infanrix-IPV/Hib | “Infanrix™-IPV/Hib at 2 months of age followed by Pediacel® at 4 and 6 months.” NCT00990080 ↗ |
| Known as | InfanrixTM | “Subjects received 3 primary doses of PoliorixTM and InfanrixTM vaccines at 3, 4.5 and 6 months of age.” NCT01094171 ↗ |
| Modality | Vaccine | “Infanrix vaccine” NCT00148941 ↗ |
| Route | Intramuscular | “1 intramuscular injection” NCT00197236 ↗ |